L&K Biomed Ltd. (KOSDAQ:156100)

L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 182.86 billion. The enterprise value is 187.96 billion.

Market Cap	182.86B
Enterprise Value	187.96B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 20.18 million shares outstanding. The number of shares has increased by 15.02% in one year.

Current Share Class	20.18M
Shares Outstanding	20.18M
Shares Change (YoY)	+15.02%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	13.14%
Owned by Institutions (%)	0.56%
Float	17.53M

Valuation Ratios

The trailing PE ratio is 101.18.

PE Ratio	101.18
Forward PE	n/a
PS Ratio	4.57
PB Ratio	4.94
P/TBV Ratio	4.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 29.01, with an EV/FCF ratio of -14.37.

EV / Earnings	92.73
EV / Sales	4.70
EV / EBITDA	29.01
EV / EBIT	55.26
EV / FCF	-14.37

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.65.

Current Ratio	1.66
Quick Ratio	0.82
Debt / Equity	0.65
Debt / EBITDA	3.72
Debt / FCF	-1.84
Interest Coverage	1.00

Financial Efficiency

Return on equity (ROE) is 5.81% and return on invested capital (ROIC) is 3.64%.

Return on Equity (ROE)	5.81%
Return on Assets (ROA)	2.68%
Return on Invested Capital (ROIC)	3.64%
Return on Capital Employed (ROCE)	7.78%
Revenue Per Employee	416.51M
Profits Per Employee	21.11M
Employee Count	60
Asset Turnover	0.50
Inventory Turnover	0.29

Taxes

In the past 12 months, L&K Biomed has paid 751.48 million in taxes.

Income Tax	751.48M
Effective Tax Rate	27.22%

Stock Price Statistics

The stock price has increased by +48.27% in the last 52 weeks. The beta is 1.84, so L&K Biomed's price volatility has been higher than the market average.

Beta (5Y)	1.84
52-Week Price Change	+48.27%
50-Day Moving Average	7,584.40
200-Day Moving Average	6,823.20
Relative Strength Index (RSI)	63.82
Average Volume (20 Days)	362,830

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 39.99 billion and earned 2.03 billion in profits. Earnings per share was 89.54.

Revenue	39.99B
Gross Profit	32.81B
Operating Income	3.40B
Pretax Income	2.76B
Net Income	2.03B
EBITDA	6.48B
EBIT	3.40B
Earnings Per Share (EPS)	89.54

Balance Sheet

The company has 13.35 billion in cash and 24.08 billion in debt, giving a net cash position of -10.73 billion or -531.85 per share.

Cash & Cash Equivalents	13.35B
Total Debt	24.08B
Net Cash	-10.73B
Net Cash Per Share	-531.85
Equity (Book Value)	37.03B
Book Value Per Share	2,140.34
Working Capital	24.07B

Cash Flow

In the last 12 months, operating cash flow was -11.09 billion and capital expenditures -1.99 billion, giving a free cash flow of -13.08 billion.

Operating Cash Flow	-11.09B
Capital Expenditures	-1.99B
Free Cash Flow	-13.08B
FCF Per Share	-647.88

Margins

Gross margin is 82.06%, with operating and profit margins of 8.51% and 5.07%.

Gross Margin	82.06%
Operating Margin	8.51%
Pretax Margin	6.90%
Profit Margin	5.07%
EBITDA Margin	16.21%
EBIT Margin	8.51%
FCF Margin	n/a

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.02%
Shareholder Yield	n/a
Earnings Yield	1.11%
FCF Yield	-7.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 2.46 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.46
Piotroski F-Score	5